These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16988163)

  • 21. Inhibitors of tumor necrosis factor for rheumatoid arthritis.
    Moreland LW
    J Rheumatol Suppl; 1999 May; 57():7-15. PubMed ID: 10328137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
    Ostergaard M; Unkerskov J; Linde L; Krogh NS; Ravn T; Ringsdal VS; Petri A; Andersen LS; Tarp U; Hansen A; Hjardem E; Hetland ML
    Scand J Rheumatol; 2007; 36(2):151-4. PubMed ID: 17476624
    [No Abstract]   [Full Text] [Related]  

  • 23. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
    Sweiss NJ; Curran J; Baughman RP
    Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 26. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
    Lehnen M; Goos M; Dissemond J
    Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
    Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
    Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
    [No Abstract]   [Full Text] [Related]  

  • 29. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Scand J Rheumatol; 2011 Mar; 40(2):150-2. PubMed ID: 20868307
    [No Abstract]   [Full Text] [Related]  

  • 30. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
    Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
    Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 32. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
    De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G
    Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab.
    Prescrire Int; 2007 Feb; 16(87):14. PubMed ID: 17326273
    [No Abstract]   [Full Text] [Related]  

  • 35. Pulmonary sarcoidosis.
    Baughman RP
    Clin Chest Med; 2004 Sep; 25(3):521-30, vi. PubMed ID: 15331189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 37. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.
    Wagner AD; Andresen J; Jendro MC; Hülsemann JL; Zeidler H
    Arthritis Rheum; 2002 Jul; 46(7):1965-8. PubMed ID: 12124882
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis.
    Moreland LW
    Isr Med Assoc J; 2001 Sep; 3(9):686-90. PubMed ID: 11574988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 40. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.